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Purpose. To investigate the effects of age on the prevalence of ocular surface diseases (OSD), adherence to treatment, and recovery
rates. Patients and Methods. Retrospective analysis of 3000 clinical records from a first-level general ophthalmology clinic. Patients
withOSDwere prospectively submitted a questionnaire to assess compliance and recovery rates.Results. OSDprevalencewas 10.3%.
Patients with OSD were significantly older than patients without it: 67.5 ± 20.3 versus 57.0 ± 22.0 years (𝑃 = 0.036). No significant
difference in season distribution was shown. Dry eye disease (DED) represented 58% of OSD; its prevalence increased with age
until 80 years old and suddenly decreased thereafter. Asymptomatic DED was 37%. Adherence to treatment in OSD was very high
(94%); recovery rates were lower in patients aged 21–40 and 61–80 (resp., 65.5% and 77.8%) and this was associated with higher
OSDI scores. Tear substitutes represented 50% of all prescribed medications; their use increased with age. Discussion. In a “real-
life” low-tech setting, OSD showed a prevalence of 10.3%. DED was the most prevalent disease, and it was asymptomatic in more
than 1/3 of cases.
1. Introduction
The ocular surface system (OSS) is defined as the wet-
surfaced epithelia of the cornea, conjunctiva, lacrimal gland,
accessory lacrimal glands, nasolacrimal duct, meibomian
gland, and their apical and basal matrices, linked as a
functional system by both continuity of epithelia, by inner-
vation, and the endocrine and immune systems. Several
age-related changes occur in most components of the OSS:
meibomian glands decrease in density and their ducts may
keratinize causing occlusion and consequent alteration in
lipid secretion; lacrimal gland secretion diminishes and its
composition changes; corneal nerve density decreases [1–
5]. These changes are frequently associated with inadequate
volume of tears, tear film instability, increased evaporation,
and abnormal immune responses. Tear film impairment is
therefore associated with a number of different ocular surface
diseases (OSD), whichmay range fromdry eye disease (DED)
to infections and immune diseases [6].
All these conditions negatively impact quality of life
(QoL). Assessment of the vision-related QoL is important in
the management of patients suffering from OSD: it reflects
the burden of disease experienced by the patient, overall
assessing the impact of OSD on the individual and it helps
monitor the changes occurring in patients with OSD. The
Ocular Surface Disease Index (OSDI) is a 12-item question-
naire designed to provide a rapid assessment of the symptoms
of OSD consistent with chronic dry eye, its severity, and its
impact on vision-related functioning.
OSDI has been shown to have a high reliability, repro-
ducibility, and validity [7]. It correlates weakly but positively
with objective markers of OSD such as tear film break-up
time, Schirmer test, and lissamine green surface staining. It
has been validated with good sensitivity and specificity to
detect normal subjects and patients with a value of≤12; scores
13 or greater indicate OSD [8, 9].
Epidemiology studies of OSD are available only for DED
and allergic conjunctivitis. DED has an extremely variable
prevalence, as it is reported to affect 5 to 34% of the
population, lying close to the higher bound of the range in
subjects 50 years old or more. Females are more affected than
males (17.0% versus 11.1% [10]), having nearly a 3-fold higher
risk of DED [11–13]. Allergic conjunctivitis has been reported
to range from 10 to 20% of the population [14].
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Figure 1: Flow chart of the events of the study.
To the best of our knowledge there are no studies explor-
ing the effect of age on the prevalence of OSD. Therefore,
through a hospital setting-based review of first-level general
ophthalmology visits, we investigated the association of OSD
and age as well as either patient’s adherence to treatment and
recovery rates or therapy and eye-drop instillation procedure
efficacy based on patient’s age.
2. Materials and Methods
This was a retrospective cross-sectional study with a prospec-
tive part consisting of the administration of a questionnaire
on the group of patients with OSD. It was conducted at the
Eye Clinic of San Paolo Hospital of Milan between January
and December 2012.
3000 clinical records obtained from a first-level general
ophthalmology clinic (the first 250 per month) were analysed
and divided into 4 groups based on the type of visit (Figure 1):
1010 first ophthalmic visits (33.7%), 1157 control visits
(38.6%), 152 access from emergency department (5%), and
681 fundus oculi examinations (22.7%).
Included were patients undergoing first ophthalmic vis-
its and control visits. Exclusion criteria were emergency
department visits, fundus oculi examinations, and inability
to retrieve information of the ocular surface from themedical
chart. The presence of ocular or systemic comorbidities was
not an exclusion criterion as well as themedical prescriptions
received at the end of the visit.
After applying exclusion criteria, the original dataset was
restricted to 1162 patients, whose main characteristics are
summarized in Table 1.
Table 1: Demographic and ophthalmic characteristics of study
participants.
Overall OSD NO OSD
Number of patients 1162 120 1042
Age, years (SD) 61.3 (21.2) 67.5 (20.3) 57.0 (22.0)
Sex, F/M 616/546 64/56 552/490
Refraction, diopters (SD) −1.20 (1.9) −1.13 (1.7) −1.31 (2.1)
IOP, mmHg (SD) 15.6 (4.2) 15.5 (3.9) 15.7 (4.4)
OSD was diagnosed in the presence of one or more of the
following:
(1) one or more of the following symptoms related
to OSD: dryness, grittiness, burning, foreign body
sensation, and visual disturbance;
(2) tear film abnormalities (Schirmer 𝐼 test results ≤
5mm/5 minutes or tear film break-up time < 10
seconds);
(3) any ocular surface abnormality.
The prevalence of OSD was calculated, and sex, age, season-
ality, diagnosis, and therapeutic prescriptions were recorded.
Within one month after the visit, patients with OSD were
contacted by phone and submitted a questionnaire to assess
their adherence to the therapy, the persistence/disappearance
of symptoms, and their OSDI score. OSDI was normal (0–
12 points) or showed mild (13–22 points), moderate (23–32
points), or severe (33–100 points) disease.
With the questionnaire, we inspected the adherence to
treatments; the ability to self-administer treatments and to
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Table 2: Prevalence and distribution of OSD etiology by age group.
Age (y) Overall OSD F/M Infection Allergy Eyelid pathology Trauma Dry eye OSDI < 12
1–10 27 4 2/2 1 0 1 0 2 1
11–20 87 6 3/3 0 2 0 0 4 1
21–30 53 10 6/4 3 1 1 1 4 2
31–40 82 14 6/8 0 5 0 2 7 2
41–50 148 18 10/8 3 2 1 0 12 3
51–60 143 17 9/8 3 4 0 0 10 3
61–70 205 23 13/10 5 2 0 0 16 9
71–80 277 24 13/11 6 3 1 1 13 5
81–90 132 4 2/2 2 0 0 0 2 0
91–100 8 0 0 0 0 0 0 0 0
1162 120 64/56 23 19 4 4 70 26
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Figure 2: Percentage of subjects suffering and not suffering from
OSD by age group. Black bars: presence of OSD; white bars: absence
of OSD.
instill the proper dosage into the eyes; treatment-related
satisfaction; and the management of persistent symptoms.
71 out of 120 subjects suffering from OSD answered the
questionnaire, 9 refused, 4 did not understand Italian and
English language, 1 had died, 29 patients could not be
contacted, and 6 patients were not called because they were
recommended a surgical treatment.
3. Results
The prevalence of OSD was 10.3% (120/1162).
The mean age for subjects without OSD was 57.0 ± 22.0
years (range: 1–100) and for OSD 67.5 ± 20.3 years (range: 3–
84;𝑃 = 0.01), the ratio between females andmales was 64/56.
OSD prevalence was equally distributed from childhood
to the middle old age, decreasing after 80 years old (Table 2,
Figure 2), without significant differences in seasonal distribu-
tion.
We classified OSD patients in 5 categories: DED (58.3%),
infections (19.2%), allergies (15.8%), eyelid pathologies
(3.3%), and trauma (3.3%). The distribution of the etiologies
was different at varying ages: infections showed a constant
distribution across all age groups; about 75% (14/19) of the
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Figure 3: Percentage of overall and asymptomatic dry eye in OSD
patients by age group. Black bars: overall dry eye; white bars:
asymptomatic dry eye (OSDI ≤ 12).
cases of allergy affected subjects younger than 60; and eyelid
pathologies equally affected both the young and the elderly,
but the causes were different (hordeolum and chalazion were
more prevalent under 40 years of age, whereas blepharitis
was progressively increasing from 30 years of age). Few
traumas were reported, and they also occurred in two age
groups based on different etiologies: foreign bodies in the
class of 21–40 years; falls in the classes of 71–100 years.
DED represented 58% (70/120) of OSD in the population.
The number of cases with DED increased with age until
80 years old, and it suddenly decreased for patients with 81
years old or more (Figure 3). DED was distinguished in two
groups: asymptomatic (OSDI ≤ 12) and symptomatic (OSDI
> 13); in our dataset, 37% of subjects had asymptomatic DED,
with a percentage apparently increasing over 60 years of age
(Figure 3). Female/male ratio for DED was 38/32.
Recovery rates for OSD ranged from 60 to 100% depend-
ing on age (Figure 4).
Compliance was high among the 71 patients submitted to
the questionnaire, as 67 (94%) followed the medical therapy
as prescribed by the ophthalmologist. Lack of resolution
occurred in 11/67 patients (16.4%); these patients asked a
second opinion (39%), required further control visits (21%),
underwent surgical treatment (11%), modified the therapy
4 Journal of Ophthalmology
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Figure 4: Percentage of OSD recovery rates by age group.
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Figure 5: Percentage of subjects able and not able to self-administer
eye drops by age group.
without consulting the doctor (7%), tolerated symptoms
(4%), or recovered without any medical therapy (18%). Only
4 patients (6%) did not adhere to the prescribed treatment
either because they spontaneously recovered (50%) either
because of the onset of an allergic reaction (25%) or a lack
of faith in the doctor (25%). Unexpectedly, most of the
nonadherent patients were graduated (95.9%); no correlation
between age and adherence to treatment was found.
Patients were also asked if they were able to self-
administer eye drops: 28.4% needed to be helped—especially
subjects younger than 10 and aged 71–80 years old (88.9%
and 34.3%, resp.)—and most of them reported a difficulty in
aiming a drop onto their eye (Figure 5). Nevertheless, 92%
patients never forgot to put eye drops in.
OSDI scores were usually ≤12, but the higher percentages
of OSDI scores >13 were found in subjects aged 31–80 years
old (Figure 6).
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Figure 6: Percentage of OSDI scores by age group.
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Figure 7: Therapy distribution.
Therapy prescription in OSD was considered: tear sub-
stitutes represented 50.9% of the topical medications, fol-
lowed by antibiotics (18.2%), steroids (12.8%), FANS (9.1%),
antihistamines (5.5%), and antivirals (3.6%) (Figure 7). Tear
substitutes were increasingly prescribed with increasing age,
with a peak for patients aged 61–80 years old (Figure 8).
4. Discussion
The results of studies on epidemiology of a disease depend
mostly on two factors: the features of the population and the
diagnostic criteria and instruments used for diagnosis.
This paper included a relatively small sample of 1162
patients, representative of the population of subjects seen
on a first-level general ophthalmology clinic. We collected
a similar number of consecutive cases per month over a 1-
year interval, so that the dataset is not influenced by seasonal
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Figure 8: Percentage of tear substitutes by age group.
variations of diseases. The study was a retrospective evalua-
tion of routine visits performed using slit-lamp examination
and, at discretion of the physician, dying with fluorescein
to evaluate parameters related to dry eye (break-up time,
epithelial staining, and clearance of fluorescein). Due to the
use of low-techmethods, underestimation of conditions such
as DED, particularly in asymptomatic cases, is extremely
likely; moreover, the population of this study is not fully
representative of the whole population, as in our clinic,
patients with glaucoma or corneal pathologies (who have a
very high prevalence of OSD [12, 15, 16]) are directly referred
to tertiary services. Nevertheless, we found a prevalence of
OSD of about 10%, which is confirmatory of the literature.
Patients with OSD were significantly older than patients
without it [6, 12, 13].
Unexpectedly, the distribution of OSD per decade was
different than reported in the literature, as we found that
the prevalence of OSD was higher in patients with 20 to 40
years. This data is influenced by the different prevalence of
allergy over age [14, 17], the effect of working activity (the
study included patients with foreign body), and the relatively
higher-than-expected prevalence of DED in young patients
[13, 18].This prevalence is possibly due to the large prevalence
of video-terminalists and users of contact lenses [19–22], a
fact that is also linked to the lower rate of recovery rate shown
in Figure 4.
The prevalence of OSD suddenly decreased after 80 years
of age, a fact that may be explained considering that patients
tend to consider this problem as “minor” when compared to
general diseases and may not require ophthalmic evaluation.
Eye doctors might also tend to overlook mild cases on this
group of patients (as a matter of fact, the prevalence of
asymptomatic DED, which peaked in the interval of 60–80
years of age, was reported as null over 80 years).
The major cause of OSD was, as expected, DED, which
affected about 60% of patients with OSD, and a mild but
constantly higher prevalence was found for females of age
between 20 and 80 years. OSD influence on QoL was indi-
rectly estimated through OSDI score: the higher the score,
the worse the QoL [23, 24]. OSDI had a peak of severity in
the decade 51–60, even if data in the range of ages of 31–80
were overall similar.
The adherence to treatment and the recovery rates found
in this paper were higher than previously reported [25, 26].
The lack of adherence in graduated patients with OSD is
possibly linked to the awareness that OSDs are frequently
benign and self-limiting.
Eye drops prescription increased with age, with a peak
for patients aged 61–80 years old. Tear substitutes were the
most frequently administered treatment (more than 50% of
all treatments): formulations containing sodium hyaluronate
and/or carboxymethylcellulose were the most commonly
prescribed, thus reflecting efficacy data from several studies
[27–29]. Preservative-free eye drops were introduced to
reduce toxic or allergic reactions when applied to the injured
ocular surface; treatment with topical coenzyme Q10 also
improved ocular surface stability [30].
In conclusion, this paper reported the prevalence of OSD
in a group of patients visited with low-tech instruments in
a “real-life” setting. The prevalence found was about 10%,
with DED being the most prevalent disease (60% of cases).
We investigated the distribution of different OSDs at varying
ages, the prevalence of asymptomatic disease, and the impli-
cations on the efficacy and distribution of treatments as well
as the adherence to them.
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